Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Post-Mkt 12-11 18:57:14 EST

0.9048

+0.0548

+6.45%

盘后0.9061

+0.0013+0.14%

18:47 EST

High0.9900	Low0.8944	Vol5.81M
Open0.9600	D1 Closing0.8500	Amplitude11.25%
Mkt Cap116.87M	Tradable Cap116.81M	Total Shares129.17M
T/O5.54M	T/O Rate4.50%	Tradable Shares129.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":0.9048,"timestamp":1765486800000,"preClose":0.85,"halted":0,"volume":5809609,"hourTrading":{"tag":"盘后","latestPrice":0.9061,"preClose":0.9048,"latestTime":"18:47 EST","volume":24342,"amount":21926.7770232,"timestamp":1765496860352},"delay":0,"floatShares":129099914,"shares":129171424,"eps":-0.234807,"marketStatus":"Post-Mkt","change":0.0548,"latestTime":"12-11 18:57:14 EST","open":0.96,"high":0.99,"low":0.8944,"amount":5542420.60869107,"amplitude":0.112471,"askPrice":0.95,"askSize":73,"bidPrice":0.905,"bidSize":106,"shortable":3,"etf":0,"ttmEps":-0.234807,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":0.85,"preHourTrading":{"tag":"盘前","latestPrice":0.9648,"preClose":0.85,"latestTime":"09:29 EST","volume":1862643,"amount":1821805.5953050798,"timestamp":1765463382884},"postHourTrading":{"tag":"盘后","latestPrice":0.9061,"preClose":0.9048,"latestTime":"18:47 EST","volume":24342,"amount":21926.7770232,"timestamp":1765496860352},"volumeRatio":8.025878,"impliedVol":1.4053,"impliedVolPercentile":0.796},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2590543348","title":"Why Are Shares Of Atossa Therapeutics Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543348","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:26","pubTimestamp":1765473960,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4548","BK4007","BK4139","BK4551","BK4585","ATOS","BK4539","Z","BK4079","LENZ","BK4588"],"gpt_icon":0},{"id":"2590516876","title":"FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516876","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516876?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:01","pubTimestamp":1765458117,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has received Rare Pediatric Disease  designation from the U.S. Food and Drug Administration  for its drug candidate -Endoxifen for the treatment of Duchenne Muscular Dystrophy . This regulatory milestone may qualify Atossa for a Priority Review Voucher upon future approval, which could be used for expedited FDA review of another application or sold to another company. The designation recognizes -Endoxifen's potential as a treatment for DMD, a severe childhood neuromuscular disease, and highlights its differentiated mechanism that does not target specific exon defects, potentially broadening its applicability among patients. No other organizations were mentioned as recipients of this regulatory designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL904ncn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2590369349","title":"Atossa Therapeutics Granted U.S. Patent for Enteric Oral (Z)-Endoxifen Formulations and Treatment Methods","url":"https://stock-news.laohu8.com/highlight/detail?id=2590369349","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590369349?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:02","pubTimestamp":1765285339,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. announced the issuance of U.S. Patent No. 12,479,790 B2, titled \"Methods for Making and Using Endoxifen.\" The new patent covers enteric oral formulations of highly pure -endoxifen free base, methods of using these compositions to treat hormone-dependent breast disorders and other estrogen-related conditions, as well as specific solid oral dosage forms and stable formulations that provide sustained systemic exposure to -endoxifen. This patent is expected to strengthen Atossa's intellectual property portfolio supporting its endoxifen therapeutic programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on Dece","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1fjpgk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2590346078","title":"Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346078?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:00","pubTimestamp":1765285206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA3BYZVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2588305342","title":"Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588305342","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588305342?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680560,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc., in collaboration with Insilico Medicine, has announced the publication of a joint study evaluating -endoxifen as a potential therapeutic candidate for glioblastoma multiforme . The results of the study, which utilized Insilico's AI-powered PandaOmics platform to systematically explore new oncology indications for endoxifen, have been published in Nature Scientific Reports. The study identified GBM as a top candidate for further investigation of -endoxifen, an active metabolite of tamoxifen with known activity in endocrine-resistant breast cancer. The announcement did not specify the initiation of a clinical trial, but highlighted the publication of these preclinical findings and the potential for future therapeutic programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3M5N0x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BZ","CRNC","TCOM","BBWI","ALLT","CGON","CPRT","ACM","CRGO","ENR","XP","ANRO","BNTC","DE","NVDA","ATRA","CLCO","WMT","CDLR","AS","ARBE","BV","EARN","BMA","NTES","WB","BULL","ATOS","AHL","TGT","CPA","VIPS","ZTO","AREC","ATKR","DLB","ADIL","POWL","CRDL","CLSD","BRBR","AZTA","DY","TBBB","ENTA","ARMK"],"gpt_icon":1},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BZ","CRNC","TCOM","BBWI","ALLT","CGON","ACM","BTBT","CRGO","XP","ANRO","BNTC","DE","NVDA","ATRA","CLCO","CDLR","AS","ARBE","BV","NTES","BMA","WB","ATAI","ATOS","BBAR","DEFT","AHL","BNZI","TGT","CPA","ZTO","AREC","ATKR","DLB","ADIL","POWL","CRDL","CLSD","BRBR","AZTA","DY","ARMK","LGN"],"gpt_icon":1},{"id":"2582249371","title":"Atossa Therapeutics Q3 net loss widens as operating costs rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2582249371","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582249371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:24","pubTimestamp":1762953858,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Q3 net loss widens as operating costs riseOverviewAtossa Therapeutics Q3 net loss widens to $8.7 mln, operating expenses rise to $9.3 mlnCompany advances (Z)-endoxifen program with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2582371628","title":"Atossa Therapeutics Secures Israeli Patent for (Z)-Endoxifen, Strengthening Global IP Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371628","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371628?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:15","pubTimestamp":1762953333,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics announced the issuance of a new Israeli patent  titled \"Methods for Making and Using Endoxifen.\" The patent was granted on July 2, 2025, and claims priority to multiple U.S. provisional applications filed in 2017 and 2018. This development marks continued progress in strengthening the company's global intellectual property portfolio for its lead program, -endoxifen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8dpC0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2582371548","title":"Atossa Therapeutics Q3 Pretax Profit USD -8.692 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371548?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:15","pubTimestamp":1762953301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXADFDB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2582371544","title":"Atossa Therapeutics Q3 Operating Expenses USD 9.251 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371544?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:15","pubTimestamp":1762953301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXADFDB1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2582388013","title":"Top News Today/Canada: Barrick's Interim CEO Gets to Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388013?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:30","pubTimestamp":1762810200,"startTime":"0","endTime":"0","summary":"Barrick Looks to Get Handle on North American Operations, Find Growth. Barrick Mining is diving into how its core gold operations in Nevada are being run and is looking for opportunities to boost production, steps that come after parting ways with its former chief executive.Mark Hill, Barrick's interim CEO, said that the mining company is determined to grow and not just replace the resources it digs up, and to produce gold and copper safely.Since taking on the role and being named chief operating officer in late September, Hill said he has met with Barrick's teams around the world. He also spent several weeks in Nevada, which alongside an asset in the Dominican Republic, is a focus of the company's review.Barrick Looking to Reset Safety Culture  Barrick Continues Efforts to Free Workers Jailed in Mali. Burger King Strikes Joint Venture to Double Presence in China. C2AE offers a range of engineering services to clients including state and local governments, transportation agencies, and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WKHS","BK4139","GNPX","BK4021","CENN","ATOS","BK4179","DOX","LU0205194284.USD","WHLM","NMM","BK4134","PVLA","SSTI","LU0205193047.USD","BK4082","EVI","CLDX","GIFI","KALV","ATRA","PRLD","SLSN","LPTH","IPSC","BK4168","FTHM","QUIK","BK4138","NRDE","BK4079","STXS","MVIS","MGNX","AMTX","IE00BFMHRM44.USD","BK4109","BK4539","BK4505","BK4551","BK4547","BK4023","BK4099","BK4137","CRBU","MGTX","ACCS","SND","SYPR"],"gpt_icon":1},{"id":"2581884105","title":"Atossa Therapeutics Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884105","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581884105?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:21","pubTimestamp":1762528866,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of7cents a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to  show no change in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ24Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2577827161","title":"Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2577827161","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577827161?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:00","pubTimestamp":1761048057,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has announced progress in the RECAST platform trial, which is focused on ductal carcinoma in situ , a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of -Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL4wWWy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2576720999","title":"Health Rounds: Scientists find way to make breast cancer drug work better for younger women","url":"https://stock-news.laohu8.com/highlight/detail?id=2576720999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576720999?lang=en_us&edition=fundamental","pubTime":"2025-10-17 03:38","pubTimestamp":1760643501,"startTime":"0","endTime":"0","summary":"Health Rounds: Scientists find way to make breast cancer drug work better for younger womenHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidOct 16  - Hello Health Rounds readers!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL2N3VV0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2575290411","title":"Atossa Therapeutics appoints Mark Daniel as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290411","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290411?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:11","pubTimestamp":1760443901,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics (ATOS) appointed Mark Daniel as CFO. Daniel is a senior finance leader with more than 25 years of experience , having overseen ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-appoints-mark-daniel-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-appoints-mark-daniel-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","ATOS","BK4539"],"gpt_icon":0},{"id":"2575109297","title":"Atossa Appoints Mark Daniel, Cpa, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2575109297","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575109297?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:01","pubTimestamp":1760443301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUAB914FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2575884297","title":"BRIEF-Atossa Therapeutics - Appoints Mark Daniel As CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2575884297","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575884297?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:52","pubTimestamp":1760442760,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics - Appoints Mark Daniel As CFO - SEC FilingOct 14  - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS - APPOINTS MARK DANIEL AS CFO - SEC FILINGATOSSA THERAPEUTICS - HEATHER REES STEPS DOWN AS CFO, ASSISTS TRANSITION UNTIL NOV 15 - SEC FILINGSource text: [ID:n0001193125-25-238065]Further company coverage: ATOS.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VU308:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2575292072","title":"Atossa Therapeutics - Heather Rees Steps Down as CFO, Assists Transition Until Nov 15 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2575292072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575292072?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:51","pubTimestamp":1760442677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VU308:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2575292021","title":"Atossa Therapeutics Appoints Mark Daniel as Chief Financial Officer to Lead Commercial Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2575292021","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575292021?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:50","pubTimestamp":1760442656,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has announced the appointment of Mark Daniel as Chief Financial Officer. Daniel brings over 25 years of experience in life sciences finance and will lead Atossa's finance, systems, and capital strategy as the company prepares for commercial operations with its breast cancer treatment candidate, -endoxifen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL3QtJ5q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.151},{"period":"1month","weight":0.0146},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.0235},{"period":"1year","weight":-0.3254},{"period":"ytd","weight":-0.0997}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.293861},{"month":2,"riseRate":0.538462,"avgChangeRate":0.099322},{"month":3,"riseRate":0.384615,"avgChangeRate":0.084638},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.043139},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.014461},{"month":6,"riseRate":0.615385,"avgChangeRate":0.128869},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.109234},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.058495},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023021},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.183809},{"month":11,"riseRate":0.307692,"avgChangeRate":-0.054625},{"month":12,"riseRate":0.357143,"avgChangeRate":-0.101516}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}